The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update

Torki, Zahra; Ghavi, Davood; Hashemi, S M; Rahmati, Yazdan; Rahmanpour, Dara; Pornour, Majid; Alivand, Mohammad Reza

doi:10.1007/s00280-021-04337-8

Cited by 10 publications

(6 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxorubicin (DOX), an antibiotic, is known as one of the most widely used chemotherapeutic drugs and can be used to treat various cancers [ 1 ]. However, DOX produces some serious side effects after long-term use, especially cardiotoxicity, which is the most typical and serious adverse reaction [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice

Shen

Yang

Huang

et al. 2023

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Doxorubicin (DOX) is a broad-spectrum anti-tumor drug, but its clinical application is greatly limited because of the cardiotoxicity. Thus, exploration of effective therapies against DOX-induced cardiotoxicity is necessary. The aim of this study is to investigate the effects and possible mechanisms of Trametes Sanguinea Lyoyd fermented crude polysaccharide (TSLFACP) against DOX-induced cardiotoxicity. We investigated the protective effects of TSLFACP on myocardial injury and its possible mechanisms using two in vitro cells of DOX-treated cardiomyocytes H9C2 and embryonic myocardial cell line CCC-HEH-2 and a in vivo mouse model of DOX-induced myocardial injury. We found that TSLFACP could reverse DOX-induced toxicity in H9C2 and CCC-HEH-2 cells. Similarly, we found that when pretreatment with TSLFACP (200 mg/kg, i.g.) daily for 6 days, DOX-induced myocardial damage was attenuated, including the decrease in serum myocardial injury index, and the amelioration in cardiac histopathological morphology. Additionally, immunohistochemistry and western blotting were used to identify the underlying and possible signal pathways. We found that TSLFACP attenuated the expression of LC3-II, Beclin-1 and PRAP induced by DOX. In conclusion, our results demonstrated that TSLFACP could protect against DOX-induced cardiotoxicity by inhibiting autophagy and apoptosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice

Shen

Yang

Huang

et al. 2023

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

“…Figure S5A of the Supporting Information complements this information with the gene ontology (GO) terms, including biological process, cellular component, and molecular function, that are enriched with these 13898 genes. Pathways associated with doxorubicin's mechanism of action such as DNA damage response [ 68,69 ] and cell signaling, [ 70 ] were found to be enriched. This suggests that dysregulation of the predicted target genes involved in these pathways could promote doxorubicin resistance.…”

Section: Resultsmentioning

confidence: 99%

“…[ 73 ] However, defect in these regulators can lead to doxorubicin failing to induce cell cycle arrest and apoptosis. [ 68,69 ] The 23 BC‐specific genes regulate processes associated with doxorubicin's mechanism of action and the breast cancer pathways in WikiPathway cancer (Figure 8). These genes are also part of drug resistance KEGG pathways, such as second‐ranked platinum drug resistance and third‐ranked endocrine resistance pathways (Figure S5C, Supporting Information), which are not found in enrichment analysis of the 13898 genes (Table S5, Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles

et al. 2022

View full text Add to dashboard Cite

Doxorubicin is a common treatment for breast cancer. However, not all patients respond to this drug, which sometimes causes life-threatening side effects. Accurately anticipating doxorubicin-resistant patients would therefore permit to spare them this risk while considering alternative treatments without delay. Stratifying patients based on molecular markers in their pretreatment tumors is a promising approach to advance toward this ambitious goal, but single-gene gene markers such as HER2 expression have not shown to be sufficiently predictive. The recent availability of matched doxorubicin-response and diverse molecular profiles across breast cancer patients permits now analysis at a much larger scale. 16 machine learning algorithms and 8 molecular profiles are systematically evaluated on the same cohort of patients. Only 2 of the 128 resulting models are substantially predictive, showing that they can be easily missed by a standard-scale analysis. The best model is classification and regression tree (CART) nonlinearly combining 4 selected miRNA isoforms to predict doxorubicin response (median Matthew correlation coefficient (MCC) and area under the curve (AUC) of 0.56 and 0.80, respectively). By contrast, HER2 expression is significantly less predictive (median MCC and AUC of 0.14 and 0.57, respectively). As the predictive accuracy of this CART model increases with larger training sets, its update with future data should result in even better accuracy.

show abstract

“…In a recent study, the combination of DOX and miRNA-495 in a tumor cell membrane-coated silica NP successfully overcame MDR in lung cancer therapy [154]. The study's findings showed that miRNA-495 effectively downregulated P-gp expression in multidrug-resistant oncogenic cells [155].…”

Section: Efflux Transporters Targetingmentioning

confidence: 99%

Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics

et al. 2023

View full text Add to dashboard Cite

Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis and treatment. Nanomaterials are extensively employed in the field of oncology because of their minute size and ultra-specificity. A wide range of nanocarriers, such as dendrimers, micelles, PEGylated liposomes, and polymeric nanoparticles are used to facilitate the efficient transport of anti-cancer drugs at the target tumor site. Real-time labeling and monitoring of cancer cells using quantum dots is essential for determining the level of therapy needed for treatment. The drug is targeted to the tumor site either by passive or active means. Passive targeting makes use of the tumor microenvironment and enhanced permeability and retention effect, while active targeting involves the use of ligand-coated nanoparticles. Nanotechnology is being used to diagnose the early stage of cancer by detecting cancer-specific biomarkers using tumor imaging. The implication of nanotechnology in cancer therapy employs photoinduced nanosensitizers, reverse multidrug resistance, and enabling efficient delivery of CRISPR/Cas9 and RNA molecules for therapeutic applications. However, despite recent advancements in nano-oncology, there is a need to delve deeper into the domain of designing and applying nanoparticles for improved cancer diagnostics.

show abstract

The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update

Cited by 10 publications

References 183 publications

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice

Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles

Recent Advances in Nanomaterials-Based Targeted Drug Delivery for Preclinical Cancer Diagnosis and Therapeutics

Contact Info

Product

Resources

About